https://fhu-mosaic.com/operandi/

Internal radiotherapies (radioembolization and internal vectorized radiotherapy) used to treat certain digestive cancers (HCC and NET) are insufficiently accompanied by methods for patient stratification and early identification of responders. OPERANDI is therefore proposing a “better select, better treat, better monitor” approach aimed at better selecting candidates for these treatments, improving patient survival, reducing costs for the healthcare system, and developing new industrial products.

OPERANDI intends to develop AI algorithms based on multiscale predictive and prognostic imaging, develop a holistic approach to therapy guided simultaneously by PET-MRI, decipher the phenomena of radio-resistance and tumor response to treatment, and evaluate new drug and radiopharmaceutical combinations.

This consortium brings together leading clinical and research teams: AP-HP (coordinating institution), CHU de Nantes, Inserm, Université de Paris, GIP ARRONAX, AFEF, CIRSE; as well as industrial partners at the forefront of translational technologies applied to patients: Siemens Healthineers, LXRepair, NH TherAguix.

https://recherche-hopitauxnord-u-pariscite.aphp.fr/le-projet-de-recherche-hospitalo-universitaire-rhu-liver-track-laureat-de-lappel-a-projet-de-lagence-nationale-de-la-recherche/

The RHU LIVER-TRACK research program will harness the full potential of extracellular vesicles – small fragments of cells circulating in the blood – to predict complications of liver disease” , explains Prof. Pierre-Emmanuel Rautou, coordinator of the RHU LIVER-TRACK program at Beaujon Hospital.